mGluR5, therefore, represents a promising target for the treatment of the disease, and indeed, using murine models of FXS, it has been demonstrated that reducing the expression of mGluR5 by 50% or inhibiting it pharmacologically restores some aspects of normal synaptic plasticity and behavior.7 The gene discussed is GRM5; the disease is fragile X syndrome.